Nicaise Claude 4

What Happened

• Nicaise Claude, a director of Gain Therapeutics, was granted a derivative award of 25,000 shares/options on July 15, 2026. The transaction is reported at $0.00 per share and classified as an award (derivative), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-07-15; Form 4 filed: 2026-07-17 (timely filing).
• Grant amount and price: 25,000 derivative shares/options at $0.00 per share.
• Shares owned after transaction: not specified in the provided filing excerpt.
• Footnote: The award vests in 12 equal monthly installments beginning July 24, 2026, subject to continuous service through each vesting date.
• Filing timeliness: Reported within the typical two-business-day window (no late filing indicated).

Context

• This is a compensation-related derivative grant (an option/award that vests over time), not a cash purchase or sale. Such grants are common for directors and reflect compensation terms rather than an immediate trading signal; consult company disclosures for full plan and exercise terms (the Form reports $0.00 but the award’s economic effect depends on the plan details).